FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085655576> ?p ?o ?g. }

• W3085655576 endingPage "2156" @default.
• W3085655576 startingPage "2149" @default.
• W3085655576 abstract "Immune-mediated endocrinopathies are among the most frequent immune-related adverse events (irAEs) with immune checkpoint inhibitors (ICIs) targeting programmed death-ligand 1 (PD-L1)/PD-1. However, the development of auto-immune diabetes is an uncommon event during PD(L)-1 blockade, either as monotherapy or in combination therapy. Here we report a case of a 75-year-old male with a mediastinal recurrence from a stage IA squamous cell carcinoma of the lung previously treated with stereotactic body radiotherapy (SBRT) who early developed a severe diabetic ketoacidosis (DKA) caused by new-onset auto-immune diabetes, with positive glutamic acid decarboxylase (GAD65) autoantibodies, during durvalumab consolidation therapy after concurrent chemoradiation. The patient had no personal or family history of diabetes or auto-immune diseases and was admitted after the second cycle of durvalumab to the intensive care unit (ICU) with severe DKA. During his hospitalization, insulin and fluid therapy were started and the patient had a favorable clinical course. Durvalumab treatment was interrupted and thyroiditis was verified during follow-up, without anti-thyroid antibodies, that progressed to subsequent hypothyroidism with need of thyroid hormone replacement therapy. This case highlights the rare irAE of autoimmune type 1 diabetes during anti-PD(L)-1 therapy, which can be life-threatening and requires adequate patient education and prompt medical treatment within a multidisciplinary team, including endocrinology and emergency medicine. Besides its low incidence, this case show how irAE must be taken in account about decision of ICI treatment, especially in curative setting, as they can be potentially fatal and impair overall survival. Furthermore, as reported in the present case, multiple endocrine irAEs can occur in the same patient either simultaneously or sequentially, suggesting that active surveillance is needed in those who develop endocrinopathies as a result of ICI treatment. Immune-mediated endocrinopathies are generally irreversible and cause life-long morbidity, which must be taken into consideration when deciding on further lines of treatment." @default.
• W3085655576 created "2020-09-21" @default.
• W3085655576 creator A5008894786 @default.
• W3085655576 creator A5021702161 @default.
• W3085655576 creator A5028999871 @default.
• W3085655576 creator A5044353569 @default.
• W3085655576 creator A5074506844 @default.
• W3085655576 creator A5080656694 @default.
• W3085655576 creator A5085893650 @default.
• W3085655576 creator A5089316684 @default.
• W3085655576 date "2020-10-01" @default.
• W3085655576 modified "2023-09-25" @default.
• W3085655576 title "Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report" @default.
• W3085655576 cites W2614694672 @default.
• W3085655576 cites W2635292439 @default.
• W3085655576 cites W2736166064 @default.
• W3085655576 cites W2753065806 @default.
• W3085655576 cites W2760410509 @default.
• W3085655576 cites W2768429453 @default.
• W3085655576 cites W2774799669 @default.
• W3085655576 cites W2786816161 @default.
• W3085655576 cites W2789846344 @default.
• W3085655576 cites W2808896902 @default.
• W3085655576 cites W2809211230 @default.
• W3085655576 cites W2896438236 @default.
• W3085655576 cites W2938345104 @default.
• W3085655576 cites W2953669376 @default.
• W3085655576 cites W2957441136 @default.
• W3085655576 cites W2962807330 @default.
• W3085655576 cites W2969953401 @default.
• W3085655576 cites W2979886379 @default.
• W3085655576 cites W2980537150 @default.
• W3085655576 cites W2988914828 @default.
• W3085655576 doi "https://doi.org/10.21037/tlcr-20-408" @default.
• W3085655576 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7653143" @default.
• W3085655576 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33209634" @default.
• W3085655576 hasPublicationYear "2020" @default.
• W3085655576 type Work @default.
• W3085655576 sameAs 3085655576 @default.
• W3085655576 citedByCount "5" @default.
• W3085655576 countsByYear W30856555762021 @default.
• W3085655576 countsByYear W30856555762022 @default.
• W3085655576 countsByYear W30856555762023 @default.
• W3085655576 crossrefType "journal-article" @default.
• W3085655576 hasAuthorship W3085655576A5008894786 @default.
• W3085655576 hasAuthorship W3085655576A5021702161 @default.
• W3085655576 hasAuthorship W3085655576A5028999871 @default.
• W3085655576 hasAuthorship W3085655576A5044353569 @default.
• W3085655576 hasAuthorship W3085655576A5074506844 @default.
• W3085655576 hasAuthorship W3085655576A5080656694 @default.
• W3085655576 hasAuthorship W3085655576A5085893650 @default.
• W3085655576 hasAuthorship W3085655576A5089316684 @default.
• W3085655576 hasBestOaLocation W30856555761 @default.
• W3085655576 hasConcept C126322002 @default.
• W3085655576 hasConcept C134018914 @default.
• W3085655576 hasConcept C187212893 @default.
• W3085655576 hasConcept C197934379 @default.
• W3085655576 hasConcept C203014093 @default.
• W3085655576 hasConcept C2777701055 @default.
• W3085655576 hasConcept C2777742743 @default.
• W3085655576 hasConcept C2778696486 @default.
• W3085655576 hasConcept C2780030458 @default.
• W3085655576 hasConcept C2781232474 @default.
• W3085655576 hasConcept C2781283889 @default.
• W3085655576 hasConcept C526584372 @default.
• W3085655576 hasConcept C555293320 @default.
• W3085655576 hasConcept C71924100 @default.
• W3085655576 hasConcept C8891405 @default.
• W3085655576 hasConceptScore W3085655576C126322002 @default.
• W3085655576 hasConceptScore W3085655576C134018914 @default.
• W3085655576 hasConceptScore W3085655576C187212893 @default.
• W3085655576 hasConceptScore W3085655576C197934379 @default.
• W3085655576 hasConceptScore W3085655576C203014093 @default.
• W3085655576 hasConceptScore W3085655576C2777701055 @default.
• W3085655576 hasConceptScore W3085655576C2777742743 @default.
• W3085655576 hasConceptScore W3085655576C2778696486 @default.
• W3085655576 hasConceptScore W3085655576C2780030458 @default.
• W3085655576 hasConceptScore W3085655576C2781232474 @default.
• W3085655576 hasConceptScore W3085655576C2781283889 @default.
• W3085655576 hasConceptScore W3085655576C526584372 @default.
• W3085655576 hasConceptScore W3085655576C555293320 @default.
• W3085655576 hasConceptScore W3085655576C71924100 @default.
• W3085655576 hasConceptScore W3085655576C8891405 @default.
• W3085655576 hasIssue "5" @default.
• W3085655576 hasLocation W30856555761 @default.
• W3085655576 hasLocation W30856555762 @default.
• W3085655576 hasOpenAccess W3085655576 @default.
• W3085655576 hasPrimaryLocation W30856555761 @default.
• W3085655576 hasRelatedWork W2011278875 @default.
• W3085655576 hasRelatedWork W2123932917 @default.
• W3085655576 hasRelatedWork W2373544290 @default.
• W3085655576 hasRelatedWork W2787961457 @default.
• W3085655576 hasRelatedWork W2957441136 @default.
• W3085655576 hasRelatedWork W2962807330 @default.
• W3085655576 hasRelatedWork W3085655576 @default.
• W3085655576 hasRelatedWork W3129864737 @default.
• W3085655576 hasRelatedWork W4283697218 @default.
• W3085655576 hasRelatedWork W4315927711 @default.

• next